See our Services in Action: Recent publications highlighting our recombinant antibody technology

Our custom antibody services are at the center of everything we do at Absolute Antibody. Since our founding, we have been providing antibody sequencing, engineering and recombinant expression services to our clients, as well as applying these technologies to build a unique catalog of recombinant engineered antibodies. We have seen our services used in a variety of projects, sometimes to engineer the perfect antibody to solve research dilemmas, to express an antibody in bulk quantities, or to sequence hybridomas to prevent from loss and enable long-term antibody reproduction.

Over the past year, we have seen a variety of publications citing our custom antibody services. These publications show our offerings in action, and we hope they provide some inspiration for your next project while highlighting the interesting research our clients are conducting.


Interaction between Neonatal Fc Receptor and Antibodies

Researchers from Promega Corporation were investigating the interaction between the neonatal Fc receptor and antibodies using a homogenous bioluminescent immunoassay. It is well-documented that a method for improving IgG/FcRn affinity is to introduce the YTE mutation in the Fc fragment of IgG. For this study, we used our custom engineering service to create an antibody with the sequence of rituximab but with a YTE mutation in the Fc region. Then, we used our HEXpress™ antibody production platform to express it in HEK293 cells. Read the full publication in The Journal of Immunology here.


mDKN-01 Enhances Innate Immune Responses in the Tumor Microenvironment

We produced a murine version of DKN-01 (mDKN-01) for a study conducted by a team at Leap Therapeutics, which showed how the mDKN-01 antibody enhances innate immune response in the tumor microenvironment. DKN-01 is an IgG4 clinical stage antibody that potently and specifically neutralizes human and murine Dickkopf-1 (DKK1) and has recently completed a promising study in combination with pembrolizumab in patients with gastric/gastroesophageal junction cancer. The purpose of this study was to characterize mDKN-01 and better understand its mechanism of action. Read the full publication in Molecular Cancer Research here.


Protective Pig Influenza Virus-Specific Antibodies

The Pirbright Institute developed the first-ever pig antibodies again influenza. The antibodies were generated from influenza-infected pigs, after which we recombinantly expressed 20 different clones for evaluation in serological assays. We then manufactured a top antibody candidate in bulk quantities for further research in vivo using our transient expression system. From their work, the researchers suggest that pigs are a valuable model for understanding how best to apply mAbs as therapy in humans and for monitoring antigenic drift of influenza viruses. Read the full publication in PLOS Pathogens here, or view our case study on this project here.


Interested in Learning More?

This is just a sampling of research using our custom antibody production. If you are looking for more examples or to speak with someone about starting your own recombinant antibody project, don’t hesitate to contact us. We are always excited to hear about your research and provide consultation to show you how recombinant antibody technology can take your research to the next level.